Amifostine inhibits acrylamide-induced hepatotoxicity by inhibiting oxidative stress and apoptosis

Document Type : Original Article

Authors

1 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

3 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s): Acrylamide (ACR) is a toxic chemical agent that can induce hepatotoxicity through different mechanisms including oxidative stress and apoptosis. Amifostine is an important hepatoprotective and anti-oxidant compound. In this research, the hepatoprotective effect of amifostine on ACR-induced hepatotoxicity in rats has been investigated.
Materials and Methods: Male Wistar rats were randomly divided into 7 groups, including: 1. Control group, 2. ACR (50 mg/kg, 11 days, IP), 3-5. ACR+ amifostine (25, 50, 100 mg/kg, 11 days, IP), 6. ACR+ N-acetyl cysteine (NAC) (200 mg/kg, 11 days, IP), and 7. Amifostine (100 mg/kg, 11 days, IP). At the end of the injection period, animals’ liver samples were collected to determine the content of glutathione (GSH), malondialdehyde (MDA), and apoptotic proteins (B-cell lymphoma 2 (Bcl2), Bcl-2-associated X protein (Bax), and cleaved caspase-3. Serum samples were also collected to measure alanine transaminase (ALT) and aspartate transaminase (AST) levels. 
Results: Administration of ACR increased MDA, Bax/Bcl2 ratio, cleaved caspase-3, ALT, and AST levels, and decreased GSH content compared with the control group. The administration of amifostine with ACR decreased MDA, Bax/Bcl2 ratio, cleaved caspase-3, ALT, and AST levels, and increased GSH content compared with the ACR group. Receiving NAC along with ACR reversed the alterations induced by ACR. 
Conclusion: This study shows that pretreatment with amifostine can reduce ACR-induced toxicity in the liver tissue of rats. Since oxidative stress is one of the most important mechanisms in ACR toxicity, amifostine probably reduces the toxicity of ACR by increasing the anti-oxidant and anti-apoptotic capacity of the hepatic cells.

Keywords

Main Subjects

References

1. Celik F, Cora T, Yigin A. Investigation of genotoxic and cytotoxic effects of acrylamide in HEK293 cell line. J Cancer Prev Curr Res 2018; 9:260-264.
2. Tareke E, Rydberg P, Karlsson P, Eriksson S, Törnqvist M. Acrylamide: A cooking carcinogen? Chem Res Toxicol 2000; 13:517-522.
3. Tareke E, Rydberg P, Karlsson P, Eriksson S, Törnqvist M. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric Food Chem 2002; 50:4998-5006.
4. Zamani E, Shokrzadeh M, Ziar A, Abedian-Kenari S, Shaki F. Acrylamide attenuated immune tissues’ function via induction of apoptosis and oxidative stress: Protection by l-carnitine. Hum Exp Toxicol 2018; 37:859-869.
5. Boon PE, de Mul A, van der Voet H, van Donkersgoed G, Brette M, van Klaveren JD. Calculations of dietary exposure to acrylamide. Mutat Res Genet Toxicol Environ Mutagen 2005; 580:143-155.
6. Rizk M, Abo-El-matty D, Aly H, Abd-Alla H, Saleh S, Younis E, et al. Therapeutic activity of sour orange albedo extract and abundant flavanones loaded silica nanoparticles against acrylamide-induced hepatotoxicity. Toxicol Rep 2018; 5:929-942.
7. Gedik S, Erdemli ME, Gul M, Yigitcan B, Bag HG, Aksungur Z, et al. Hepatoprotective effects of crocin on biochemical and histopathological alterations following acrylamide-induced liver injury in Wistar rats. Biomed Pharmacother 2017; 95:764-770.
8. Kandemir FM, Yıldırım S, Kucukler S, Caglayan C, Darendelioğlu E, Dortbudak MB. Protective effects of morin against acrylamide-induced hepatotoxicity and nephrotoxicity: A multi-biomarker approach. Food Chem Toxicol 2020; 138:111190.
9. Song G, Liu Z, Wang L, Shi R, Chu C, Xiang M, et al. Protective effects of lipoic acid against acrylamide-induced neurotoxicity: involvement of mitochondrial energy metabolism and autophagy. Food Funct 2017; 8:4657-4667.
10. Ghorbel I, Elwej A, Fendri N, Mnif H, Jamoussi K, Boudawara T, et al. Olive oil abrogates acrylamide induced nephrotoxicity by modulating biochemical and histological changes in rats. Ren Fail 2017; 39:236-245.
11. Cao J, Liu Y, Jia L, Jiang L-P, Geng C-Y, Yao X-F, et al. Curcumin attenuates acrylamide-induced cytotoxicity and genotoxicity in HepG2 cells by ROS scavenging. J Agric Food Chem 2008; 56:12059-12063.
12. Watzek N, Scherbl D, Feld J, Berger F, Doroshyenko O, Fuhr U, et al. Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps. Mol Nutr Food Res 2012; 56:1825-1837.
13. Besaratinia A, Pfeifer GP. A review of mechanisms of acrylamide carcinogenicity. Carcinogenesis 2007; 28:519-528.
14. Yousef M, El-Demerdash F. Acrylamide-induced oxidative stress and biochemical perturbations in rats. Toxicology 2006; 219:133-141.
15. Chen W, Shen Y, Su H, Zheng X. Hispidin derived from Phellinus linteus affords protection against acrylamide-induced oxidative stress in Caco-2 cells. Chem-Biol Interact 2014; 219:83-89.
16. Naruszewicz M, Zapolska-Downar D, Kośmider A, Nowicka G, Kozłowska-Wojciechowska M, Vikström AS, et al. Chronic intake of potato chips in humans increases the production of reactive oxygen radicals by leukocytes and increases plasma C-reactive protein: a pilot study. Am J Clin Nutr 2009; 89:773-777.
17. Exon J. A review of the toxicology of acrylamide. J Toxicol Environ Health 2006; 9:397-412.
18. Zhang X, Jiang L, Geng C, Yoshimura H, Zhong L. Inhibition of acrylamide genotoxicity in human liver-derived HepG2 cells by the anti-oxidant hydroxytyrosol. Chem-Biol Interact 2008; 176:173-178.
19. Ghareeb DA, Khalil AA, Elbassoumy AM, Hussien HM, Abo-Sraiaa MM. Ameliorated effects of garlic (Allium sativum) on biomarkers of subchronic acrylamide hepatotoxicity and brain toxicity in rats. Toxicol Environ Chem 2010; 92:1357-1372.
20. Haidari F, Mohammadshahi M, Zarei M, Fathi M. Effect of fresh lemon juice on oxidative stress and hepatotoxicity acrylamide-induced toxicity in rats. Int J Radiat Oncol Biol Phys 2017; 11:9-16.
21. Seydi E, Rajabi M, Salimi A, Pourahmad J. Involvement of mitochondrial-mediated caspase-3 activation and lysosomal labilization in acrylamide-induced liver toxicity. Toxicol Environ Chem 2015; 97:563-575.
22. Pyo MC, Shin HS, Jeon GY, Lee K-W. Synergistic interaction of ochratoxin A and acrylamide toxins in human kidney and liver cells. Biol Pharm Bull 2020; 43:1346-1355.
23. Zhang L, Wang E, Chen F, Yan H, Yuan Y. Potential protective effects of oral administration of allicin on acrylamide-induced toxicity in male mice. Food Funct 2013; 4:1229-1236.
24. El-Bohi K, Moustafa G, El sharkawi N, Sabik L. Genotoxic effects of acrylamide in adult male Albino rats liver. Am J Sci 2011; 7:1097-1108.
25. Altinoz E, Turkoz Y, Vardi N. The protective effect of N-acetylcysteine against acrylamide toxicity in liver and small and large intestine tissues. Bratisl Lek Listy 2015; 116:252-258.
26. Alturfan AA, Tozan-Beceren A, Şehirli AÖ, Demiralp E, Şener G, Omurtag GZ. Resveratrol ameliorates oxidative DNA damage and protects against acrylamide-induced oxidative stress in rats. Mol Biol Rep 2012; 39:4589-4596.
27. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, Vucinic ZM, Sinovec SM, Jacevic VM, et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004; 15:169-178.
28. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007; 12:738-747.
29. Jaćević V, Dragojević-Simić V, Tatomirović Ž, Dobrić S, Bokonjić D, Kovačević A, et al. The efficacy of amifostine against multiple-dose doxorubicin-induced toxicity in rats. Int J Mol Sci 2018; 19:2370.
30. Zhang X, Lai PP, Taylor YC. Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR1065. Int J Radiat Oncol Biol Phys 1992; 24:713-719.
31. Treskes M, Holwerda U, Nijtmans L, Fichtinger-Schepman A, Pinedo H, van der Vijgh W. Modulation of cisplatin and carboplatin with WR-2721 molecular aspects. Chem Mod Cancer Treat 1994:322-323.
32. Treskes M, Holwerda U, Nijtmans LG, Pinedo HM, van der Vijgh WJ. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother Pharmacol 1992; 29:467-470.
33. El-Ghissassi F, Verhaegh G, Hainaut P, editors. Modulation of wild-type p53 protein activity by the aminothiol amifostine. InProc Am Soc Clin Oncol; 1997; 23:2-17.
34. Capizzi R. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (ethyol®). Eur J Cancer 1996; 32:S5-S16.
35. Capizzi RL, editor The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol; 1996; 23:2-17.
36. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-110.
37. Esmaeelpanah E, Razavi BM, Vahdati Hasani F, Hosseinzadeh H. Evaluation of epigallocatechin gallate and epicatechin gallate effects on acrylamide-induced neurotoxicity in rats and cytotoxicity in PC 12 cells. Drug Chem Toxicol 2018; 41:441-448.
38. Batista C, Mota J, Souza M, Leitao B, Souza M, Brito G, et al. Amifostine and glutathione prevent ifosfamide-and acrolein-induced hemorrhagic cystitis. Cancer Chemother Pharmacol 2007; 59:71-77.
39. Meszka-Jordan A, Mahlapuu R, Soomets U, GP C. Oxidative stress due to styrene and styrene oxide exposure and the role of anti-oxidants. J Toxicol Environ Health 2009; 72:642-650.
40. Wang D, Qi J, Pan X, Yan D, Yan H. The antagonistic effect and mechanism of N-acetylcysteine on acrylamide-induced hepatic and renal toxicity. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2016; 34:13-17.
41. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86:271-278.
42. Goyal S, Arora S, Mittal R, Joshi S, Nag TC, Ray R, et al. Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol 2009; 619:75-84.
43. Wang C-S, Chang T-T, Yao W-J, Wang S-T, Chou P. Impact of increasing alanine aminotransferase levels within normal range on incident diabetes. J Formos Med Assoc 2012; 111:201-208.
44. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52:1156-1161.
45. Awad M, Abdel-Rahman M, Hassan S. Acrylamide toxicity in isolated rat hepatocytes. Toxicol In Vitro 1998; 12:699-704.
46. Akbulut S, Elbe H, Eris C, Dogan Z, Toprak G, Otan E, et al. Cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against methotrexate-induced hepatotoxicity in rats. World J Gastroenterol 2014; 20:10158–10165.
47. Zakaria El-Khayat, Abdel Aleem Hassan, Nadia A. Mohamed, Mehrez E. El-Naggar, Enayat A. Omara, Basuony DM. Hepatoprotective efficacy of amifostine nanoemulsion in cisplatin hepatotoxic rat. Res J Pharm Biol Chem Sci 2019; 10:74-82.
48. Stankiewicz A, Skrzydlewska E, Makiela M. Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. Drug Metabol Drug Interact 2002; 19:67-82.
49. Bolaman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yenisey C, et al. The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats. Tohoku J Exp Med 2005; 207:249-253.
50. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7:153-163.
51. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304:437-444.
52. Oltval ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74:609-619.
53. Lakshmi D, Gopinath K, Jayanthy G, Anjum S, Prakash D, Sudhandiran G. Ameliorating effect of fish oil on acrylamide induced oxidative stress and neuronal apoptosis in cerebral cortex. Neurochem Res 2012; 37:1859-1867.
54. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13:5127–5132.
55. Cai Z, Lou Q, Wang F, Li E, Sun J, Fang H, et al. N-acetylcysteine protects against liver injure induced by carbon tetrachloride via activation of the Nrf2/HO-1 pathway. Int J Clin Exp Pathol 2015; 8:8655–8662.
56. Tsai C-C, Chen Y-J, Yu H-R, Huang L-T, Tain Y-L, Lin I-C, et al. Long term N-acetylcysteine administration rescues liver steatosis via endoplasmic reticulum stress with unfolded protein response in mice. Lipids Health Dis 2020; 19:1-11.
57. Shi T, Yang X, Zhou H, Xi J, Sun J, Ke Y, et al. Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis. PLoS One 2018; 13:e0189856.
Iranian Journal of Basic Medical Sciences
Volume 26, Issue 6
June 2023
Pages 662-668

Files

Share

How to cite

Statistics